No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
RXRX241213P13000
- 0.00
- 0.000.00%
15min DelayTrading Dec 11 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest13.00Strike Price0.00Turnover963.03%IV-72.87%PremiumDec 13, 2024Expiry Date5.48Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6431Delta0.0667Gamma1.24Leverage Ratio-0.4972Theta-0.0006Rho-0.80Eff Leverage0.0022Vega
Intraday
- 5D
- Daily
No Data
News
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $11
Promising Developments and Positive Outlook for Recursion Pharmaceuticals Drive Buy Rating
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
TD Cowen Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)